We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
-2.33%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$244M
AUM Growth
-$11.8M
(-4.6%)
Cap. Flow
+$12.7M
Cap. Flow
% of AUM
5.19%
Top 10 Holdings %
Top 10 Hldgs %
62.11%
Holding
67
New
30
Increased
14
Reduced
7
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$15.1M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$11M |
| 3 |
Guardant Health
GH
|
+$9.53M |
| 4 |
Eli Lilly
LLY
|
+$8.42M |
| 5 |
Edwards Lifesciences
EW
|
+$7.85M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$15M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$11.3M |
| 3 |
Protagonist Therapeutics
PTGX
|
+$9.3M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
+$9.06M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$8.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.84% |
| 2 | Consumer Staples | 4.83% |
| 3 | Industrials | 0.1% |
| 4 | Real Estate | 0.04% |
| 5 | Materials | 0.04% |
Similar funds
DCM
AMPWP
DCM
IWP
PCS
ACGDR
GEA
ECM
Tri Locum Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Tri Locum Partners held 67 positions worth $244M, down 4.6% from $256M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Tri Locum Partners deployed $12.7M of net new capital in Q2 2022, opening 30 new positions and adding to 14 existing holdings. Its largest new stake was CATALENT, INC.: 108,241 shares worth $11.6M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Industrials.
On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $11.3M trimmed.
- Tri Locum Partners's largest Q2 2022 buy was CATALENT, INC.: 108,241 shares worth $11.6M.
- Tri Locum Partners added most to argenx in Q2 2022, an estimated $15.1M increase.
- Tri Locum Partners's biggest Q2 2022 reduction was Jazz Pharmaceuticals, cutting an estimated $11.3M.
- Tri Locum Partners fully exited Regeneron Pharmaceuticals in Q2 2022, selling an estimated $15M.
- Tri Locum Partners's ten largest holdings make up 62% of its $244M portfolio in Q2 2022.
- Tri Locum Partners opened 30 new positions and closed 16 in Q2 2022.
- Tri Locum Partners's portfolio value fell 4.6% quarter-over-quarter to $244M.
Based on Tri Locum Partners's 13F filing for Q2 2022, filed 15 Aug 2022.